. 2017 Jul 17;75(2):209–223. doi: 10.1007/s00018-017-2596-8

Table 2.

Cancer clinical trials of the inhibitors of the H3K27 methylation modifiers

Compound	Mechanism	Tumor type	Status	ClinicalTrials.gov identifier
CPI-1205	Unknown	B-cell lymphoma	Phase 1	NCT02395601
E7438 (EPZ-6438) (Tazemetostat)	SAM-competitive^a	B-cell lymphoma Solid tumors Diffuse large cell lymphoma Follicular lymphoma Transformed follicular lymphoma Primary mediastinal large B-cell lymphoma	Phase 1 Phase 1 Phase 2 Phase 2	NCT01897571
Tazemetostat	SAM-competitive	Mesothelioma (with or without BAP1 deficiency)	Phase 2	NCT02860286
Tazemetostat	SAM-competitive	Rhabdoid tumors INI1-negative tumors Synovial sarcoma Malignant rhabdoid tumor of ovary	Phase 1	NCT02601937
Tazemetostat	SAM-competitive	Malignant rhabdoid tumors Rhabdoid tumors of the kidney Atypical teratoid rhabdoid tumors Selected tumors with rhabdoid features INI1-negative tumors Synovial sarcoma Malignant rhabdoid tumor of ovary Renal medullary carcinoma Epithelioid sarcoma	Phase 1	NCT02601950
GSK2816126	SAM-competitive	Diffuse large B cell lympho Transformed follicular lymphoma Non-Hodgkin’s lymphomas Solid tumors Multiple myeloma	Phase 1	NCT02082977
MAK683	EED inhibitor	Diffuse large B cell lymphoma	Phase 1/2	NCT02900651
Tazemetostat	SAM-competitive	Diffuse large B cell lymphoma Follicular lymphoma Malignant rhabdoid tumor Rhabdoid tumors of the kidney Atypical teratoid rhabdoid tumors Synovial sarcoma Epithelioid sarcoma Mesothelioma Advanced solid tumors	Phase 2	NCT02875548^b

Source: http://www.clinicaltrials.gov

^a SAM: S-adenosyl-L-methionine

^b This study provides continuing availability to tazemetostat as a single agent to subjects who have completed their participation in an antecedent tazemetostat study